SELDI-TOF MS Proteomics in Breast Cancer by unknown
SELDI-TOF MS Proteomics in Breast Cancer
Bashar A. Zeidan & Ramsey I. Cutress & Claire Hastie &
Alex H. Mirnezami & Graham Packham &
Paul A. Townsend
Published online: 30 June 2009
# Humana Press 2009
Abstract
Background Proteomic profiling is a rapidly developing
technology that may enable early disease screening and
diagnosis. Surface-enhanced laser desorption ionization–
time of flight mass spectrometry (SELDI-TOF MS) has
demonstrated promising results in screening and early
detection of many diseases. In particular, it has emerged
as a high-throughput tool for detection and differentiation
of several cancer types. This review aims to appraise
published data on the impact of SELDI-TOF MS in breast
cancer.
Methods A systematic literature search between 1965 and
2009 was conducted using the PubMed, EMBASE, and
Cochrane Library databases. Studies covering different
aspects of breast cancer proteomic profiling using SELDI-
TOF MS technology were critically reviewed by researchers
and specialists in the field.
Results Fourteen key studies involving breast cancer
biomarker discovery using SELDI-TOF MS proteomic
profiling were identified. The studies differed in their
inclusion and exclusion criteria, biologic samples, prepara-
tion protocols, arrays used, and analytical settings. Taken
together, the numerous studies suggest that SELDI-TOF
MS methodology may be used as a fast and robust
approach to study the breast cancer proteome and enable
the analysis of the correlations between proteomic expres-
sion patterns and breast cancer.
Conclusion SELDI-TOF MS is a promising high-
throughput technology with potential applications in breast
cancer screening, detection, and prognostication. Further
studies are needed to resolve current limitations and
facilitate clinical utility.
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PND Pathological nipple discharge
PR Progesterone receptor
SAX Strong anion exchange (Q10)
SELDI Surface-enhanced laser desorption
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Introduction
Surface-enhanced laser desorption ionization-time of flight
mass spectrometry (SELDI-TOF MS) blends together the
principles of retention chromatography and mass spectrom-
etry (Figs. 1 and 2), providing a rapid, high-throughput, and
relatively sensitive screening method capable of analyzing
complex protein samples. This technology is also capable of
rapid separation, detection, and analysis of proteins at the
femtomole level, directly from biological samples. It is a
tool, per se, that enables multi-analyte discovery and
facilitates analyses of large numbers of different samples
with the simultaneous study of multiple biological variables.
The limitations of current diagnostic techniques for
asymptomatic breast disease have been well documented
[1–3]. While breast screening by mammography can reduce
mortality from breast cancer [4–6], the sensitivity of
mammography is limited and reported at 63–87% [7] only.
In addition, mammographic sensitivity is lower in young
women due to increased breast density [1–3], and so
younger women and patients with a genetic predisposition
for early onset breast cancer (for example BRCA1 or
BRCA2 mutations), frequently miss the diagnostic screen-
ing window [8]. These factors have prompted the search for
alternative approaches to improve the sensitivity of breast
cancer diagnosis and screening.
Alterations in individual or groups of proteins, their
abundance, structure, or function, can act as useful indicators
of pathological abnormalities prior to development of clinical
symptoms. Similar to other malignancies, the multifactorial
nature of breast cancer lends itself towards the use of
multiple biomarkers for early detection, prognostication, and
the monitoring of response to therapy. Consequently,
analysis of panels of biomarkers may prove more reliable
for the detection and subtyping of breast cancer than using
single markers. Furthermore, markers detecting early stage
disease would be valuable since they could identify the
disease at an early curable phase. For example, while ductal
carcinoma in situ (DCIS) is potentially curable if detected
early [9, 10], more than one third of all breast cancers are
disseminated at diagnosis [9]. The emerging field of
proteomics allows the discovery of early stage biomarkers
in cellular or biological fluids. SELDI-TOF MS combines an
“on-array” separation of complex protein mixtures via
retention coupled directly with mass spectrometry detection.
This technique enables profiling of proteins from different
biological samples such as cancer cell lines, serum, nipple
aspirate, plasma, urine, and tissue extracts, and has the
advantage of high sample throughput, which allows gener-
ation of sufficient data to adequately power statistical tests.
The principles and clinical applications of SELDI have been
reviewed and have been successfully used in biomarker
discovery on various tissues and samples [11, 12]. Only a
few microliters of the sample of interest are deposited on a
selective chromatographic surface (array), which retains
proteins from biological mixtures according to their
physico-chemical properties. Consequently, the proteins of
interest are captured on the chromatographic surface depend-
ing on the arrays’ properties (Table 1). Special biochemically
active surfaces can also be used to exploit specific molecular
recognition mechanisms such as antibody–antigen, enzyme–
substrate, receptor–ligand, and protein–DNA interactions.
This is a unique advantage of SELDI over other forms of MS
where crude samples cannot be reliably used for protein
analysis. Mass testing and comparison between protein peaks
can pinpoint significant differences in protein abundance
between samples. SELDI-TOF MS, therefore, allows potent
protein analysis from a variety of sample types, with minimal
sample consumption and processing.
If the analysis reveals candidate biomarkers or a
combination (panel) of biomarkers, classification rules can
then be used to discriminate between the various groups.
Validation with a larger cohort is then required ideally using
independent blinded samples from different centers to
reduce sources of bias and avoid extraneous variation.
Once the peptide peak of a potential biomarker is
established, purification and identification of the biomarker
is clearly an additional complementary step.
The use of SELDI-TOF MS and other mass spectrometry
platforms, such as matrix-assisted laser desorption ionization
(MALDI MS) for proteomic profiling of body fluids has
many potential uses and advantages as a clinical assay. These
techniques use readily accessible clinical samples and have
proven to be reliable and reproducible [11, 13, 14]. SELDI is
a modification of MALDI but has the advantage of
immobilizing proteins from complex biological samples on
selective chromatographic surfaces. It is thus designed to
detect subtle changes in protein properties by the different
conditions of each surface. Moreover, fractionation of
samples prior to analysis with SELDI increases the possibil-
ity of low abundance protein discovery. Different spectra
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may be generated from the same sample using different
surfaces and sample fractions, increasing the venues for deep
protein mining. In this article, we present a critical review of
the role of SELDI-TOF MS in breast cancer profiling. We
highlight the significant findings to date and discuss
weaknesses and limitations of existing studies with sugges-
tions for improvement and optimization of the use of SELDI-
TOF MS in this field.
Serum Proteomic Profiling in Breast Cancer
Serum has been widely used for study by SELDI
proteomics as it is relatively minimally invasive, reproduc-
ible, and cheap to obtain. Based on the hypothesis that
cancer-related protein/peptide signatures in sera can be used
in the early detection of cancer, serum proteomic expression
profiles have been studied as potential tools for early
diagnosis. During tumorogenesis, differentially expressed
serum proteins can originate from different sources. Direct
or indirect communication of cells with the blood may lead
to the release of tissue specific proteins upon cell damage or
death. Serum profiles could also reflect specific cancer
excreted proteins, host response, acute phase reactants, or
elevated normal body protein levels in response to tumors.
Since these profiles could represent altered phenotypic
events during neoplastic transformation and progression, it
is reasonable to expect characteristic proteomic profiles in
the presence of cancer.
Samples from cancer and non-
cancer patients coated onto the 
proteomic array. All proteins in the 
sample, shown on the right, are 
docked to the chip spots and ready 
for analysis
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sensitivity and specificity.
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Fig. 1 An illustration of the
SELDI-TOF MS experimental
steps. This starts with sample
preparation followed by its
application onto a chromato-
graphic array. The samples will
then be loaded into the SELDI-
TOF MS and targeted with laser.
This will ionize the proteins
within the sample and will allow
them to fly to an oppositely
charge electrode in a vacuum
chamber. A laser detector will
then measure the time of flight
(TOF) of each protein which
reflects its molecular weight.
Using special software the
masses will be presented in
waves corresponding to m/z.
This can then be analyzed using
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Serum Proteomic Profiling in Breast Cancer Prediction
One of the early pilot studies of SELDI proteomic profiling
in breast cancer was a prospective analysis of 134 pre-
treatment serum samples by Vlahou et al. [15] (Table 2), to
determine if protein profiling could distinguish between
patients and controls. Multivariate analysis revealed three
discriminatory peaks differentiating cancer from normal
Array Description Applications and requirements
IMAC30 Immobilized metal affinity capture
(IMAC), with nitriloacetic acid
surface
Transition metal activation is needed prior
to use. Phosphorylated proteins and
polyhistidine-tagged proteins capture.
Protein profiling and identification
CM10 (WCX) Weak cation exchanger with negatively
charged carboxylated surface
Protein profiling and identification
Q10 (SAX) Strong anion exchanger with positively
charged quaternary amine surface
Protein profiling and identification
H50 Hydrophobic interaction surface Protein profiling and identification
Reverse phase




Pre-activated surfaces Specific protein–protein binding
(e.g., protein–ligand or antibody–antigen
binding)
Table 1 Summary of the de-
scription and applications of
most commonly used Protein-
Chips in SELDI-TOF MS pro-
teomic profiling













































Fig. 2 An Illustration of peak clusters generated by SELDI-TOF MS
proteomic profiling. Marked values represent significant mass/charge
(m/z) protein peaks. The differential expression of proteins between
cancer and control spectra is illustrated in this figure. Few of the
differentially expressed peaks between the two groups are detected in
a very narrow region of the spectra between 3.6 and 4.2 kDa.
Horizontal and vertical axes represent m/z in Daltons and peak
intensity in microampere, respectively
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groups (Table 2). In addition, three different peaks
segregated cancer serum sample proteomic profiles from
the benign group. Cross validation analysis of cancer versus
normal samples revealed a sensitivity and specificity of
80% and 79%, respectively, and for cancer versus benign
disease of 79% and 83% respectively. The use of multiple
chromatographic binding surfaces (immobilized metal
affinity capture (IMAC) and strong anion exchange
(SAX)) further improved sensitivity and specificity in this
study.
Laronga et al. [16] utilized the optimized assay con-
ditions described by Vlahou et al. [15]. The main peaks to
discriminate between breast cancer patients and controls on
cross validation were selected. Using this approach, they
were able to differentiate between patients with cancer and
controls with a sensitivity of 87% and a specificity of 93%
on cross-validation. This is consistent with the findings of
Vlahou on which many of the parameters of this study were
based [17].
In a further pilot study, Li et al. [18] performed screening
for potential biomarkers on the serum of 169 patients with
breast cancer and healthy controls. Serum from participants
was tested by chromatography using SELDI-TOF MS
following standardized sample preparation [18]. A panel
of three markers (BC1 4.3 kDa, BC2 8.1 kDa, BC3
8.9 kDa) [18] were selected based on their ability to
distinguish between invasive disease and controls, or in situ
disease. When applied to the same cohort, they achieved
93% sensitivity and 91% specificity in distinguishing
between these groups. Nevertheless, as there were only
four patients with DCIS, and this study could not test the
ability of these markers in identifying the disease at an early
in situ stage. In a separate study, the authors tested the same
markers in a different patient population [17]. Serum
samples obtained from 176 women prior to medical
intervention were used. Similar to the original study [18],
two peaks—BC2 (8.1 kDa) and BC3 (8.9 kDa)—were
differentially overexpressed in breast cancer patients com-
pared to healthy subjects, demonstrating the reproducibility
of SELDI-TOF MS across different patient populations.
Furthermore, the authors were able to identify these peaks
as complement components C3adesArg and a C-terminal-
truncated form of this component. This illustrates one of the
concerns in such studies, where non-specific candidates
qualify as discriminatory biomarkers. This study was
unable to validate the third candidate peak previously
Table 2 Summary of the candidate biomarkers detected in different studies
Study
Vlahou et al. [15] Li et al. [18] Li et al. [17] Mathelin et al. [19]
Number 134 169 176 89
45 patients with breast
cancer, 42 benign disease,
47 healthy controls
99 stage I–III 61 patients locally invasive
breast cancers (IBC), 32
DCIS, 37 benign breast
lesions (19 atypical ductal
hyperplasia (ADH)), 46 age-
matched healthy subject
49 patients with breast
cancer, 13 patients with





Sample Serum Serum Serum Serum
Array used IMAC30, Q10 IMAC-Ni IMAC-Ni IMAC-Ni
Differential
peaks
Cancer vs. control BC1: 4.3 kDa↓a BC2: 8.1 kDa ↑a BC1: 4.3 kDa ↓a
2.95 kDa BC2: 8.1 kDa ↑a BC3: 8.9 kDa ↑a BC1a: 4.286 kDa ↓a
3.68 kDa BC3: 8.9 kDa ↑a BC1b: 4.302 kDa ↓a
4.27 kDa BC3: 8.9 kDa ↑a
Cancer vs. benign BC3a: 8.919 kDa ↑a
6.43 kDa BC3b: 8.961 kDa ↑a
7.48 kDa
8.61 kDa
Comments Using combination of peaks
from two different chips
improved sensitivity and
specificity of detection to
90 and 93% respectively




and specificity of 93%
and 91%, respectively
The study failed to validate
BC1: 4.3 kDa
Failed to recover BC2:
8.1 kDa from Li et al.
[16]
BC2 and BC3 were identified
as complement components
No correlation was found





BC2 and BC3 did not
correlate to size, grade,
nodal, or ER/PR status
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detected, BC1 (4.3 kDa), which was identified as the
truncated form of interalpha-trypsin inhibitor heavy chain
H4 [17]. This peak was underexpressed in the breast cancer
group within the first set [18] and overexpressed in the
validation breast cancer population [17]. Clearly, reproduc-
ibility and robustness of the SELDI-TOF MS technique
necessitates consistent collection, storage, handling, and
sample preparation techniques, with similar protein array
surfaces and analytical and bioinformatics settings.
In a second validation of this study, Mathelin and
coworkers [19] also found that the combination of the two
peaks BC1 (4.3 kDa) and BC3 (8.9 kDa) differentiated
between breast cancer patients and healthy subjects. The
BC2 marker recorded by Li et al. [18] was not recovered.
This later found four peaks which could correspond to the
BC1 and BC3 peaks identified in the previous work. The
first two corresponding peaks, termed BC1a (4,286 Da) and
BC1b (4,302 Da) could correspond to BC1 (4.3 kDa) from
the previous work of Li et al., and were similarly under-
expressed in the breast cancer patients. Likewise, the peaks
named BC3a (8,919 Da) and BC3b (8,961 Da) appeared to
correspond to the BC3 (8.9 kDa) peak from Li et al. and
were overexpressed in the cancer group. Division of the
four peaks into stringent (no error) and flexible (<10%
error) enabled identification of 33% and 45% of patients
with breast cancer, from patients with benign disease and
controls, respectively. Interestingly, the proteomic expres-
sion patterns in patients with benign disease were similar to
controls. In a trial to combine use of these peaks with an
existing clinical tumor marker, Ca 15.3, the predictive
power of the combination of these markers improved the
ability for cancer detection. While this partially validated
the earlier study of Li et al., the efficiency of these markers
in indentifying patients with breast cancer was moderate,
and in particular, the ability of the technique to detect early
in situ disease remained unproven.
A recent study by Van Winden and colleagues aimed to
further validate the BC1, BC2, and BC3 peaks [20]. In this
study, the SELDI spectra of 48 breast cancer patients were
compared to 48 controls. Storage duration and/or batch
effects but not participants’ age seemed to significantly
affect the overall peak intensity but not the discriminatory
pattern between the groups. Only one peak (BC1 4.3 kDa)
was validated in this study and was underexpressed in
patients with breast cancer, as previously predicted. Two
ionic peaks possibly corresponding to the BC2 and the BC3
Study
Van Winden et al. [20] Laronga et al. [16] Becker et al. [23]
Number 96 16 cancer pre- and post-surgery samples 62
48 primary invasive breast cancer vs.
48 healthy




Sample Serum Serum Serum
Array used IMAC-Ni IMAC-Cu IMAC-Cu
Differential
peaks
Cancer vs. control Pre- vs. post-surgery BRCA1 cancer vs. carrier
BC1: 4.3 kDa ↓a 6.194 kDa↑ 8.138 kDa ↑a
BC3: 8.9 kDa ↓a 2.276 kDa ↑ 5.909 kDa ↓a
3.892 kDa ↑ BRCA1 cancer vs. SBC
BRCA1 cancer vs. carrier 8.1 kDa ↑a
5.9 kDa ↓a
SLN + ve vs. SLN −ve
SAX: 5.9065 ↓a 4.0277, 7.4144 kDa
IMAC-Cu: 1.437, 1.003, 1.349 kDa
Comments The study detected a possible BC2 peak
at 8.1 kDa which was not
differentially expressed between the
two groups
All three differentially expressed peaks are
overexpressed post-surgery
BRCA1 carriers and healthy
had similar profiles
No correlation between any candidate
biomarker and tumor characteristics
5 peaks were retained by cancer patients post-
treatment, whether this correlates to residual
disease, poorer response/outcome, or DFS is
yet to be studied
BRCA1 cancer had
8.1 kDa compared to
BRCA1 carrier/SBC, but
not from healthy patients
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peaks were noted; however, their expression was incon-
sistent with the original study. This study demonstrates
the difficulties in validating the results of SELDI,
especially with the absence of subsequent protein
sequencing platforms.
A further well-designed and internally validated study
involving 310 subjects explored the ability of mass
spectrometry for distinguishing between patients with early
breast cancer (stage I) and healthy subjects [21]. Mammog-
raphy was used to exclude cancer in the control group, and
patients with a family history of breast cancer were
excluded from the control group. Belluco and colleagues
[21] used 109 controls and 109 patients with invasive
ductal carcinoma (IDC), a blinded testing set of 46 controls
and 46 patients with IDC, and finally an independent
validation set of 46 patients (15 healthy controls and 31
with IDC) whose samples were collected and analyzed
14 months later. This study focused on the enrichment and
selection of carrier proteins to which most of the lower
molecular weight (LMW) biomarkers are linked. Specifically,
an IMAC chip surface which has a high affinity for albumin
was used to enable analysis of bound LMW proteins. In the
training set, seven ion peaks were identified that discriminated
between the groups with a sensitivity and specificity of 95%
and 85%, respectively (Table 2). In the validation study, all
the 17 T1a tumors were identified. This work demonstrates
that SELDI profiling of serum can generate a robust
classification of stage I breast cancer. When the SELDI-
TOF results were used to further classify patients with
equivocal mammography (34 patients), 94% of the patients
with Breast Imaging Reporting and Data System score of 4
were correctly diagnosed. This potential clinical utility of
mass spectrometry in improving the positive predictive value
of mammography was clear in this work. This has led to the
development of an ongoing prospective multicenter project
between Italy and the USA involving 4,000 subjects to further
consolidate these findings [21].
Serum Proteomic Biomarkers in BRCA1 Mutation Patients
BRCA1 mutations account for 7–10% of breast cancers and
are associated with early development of breast cancer and
poor outcome [22]. Up to 80% of patients with BRCA1
mutations ultimately develop breast cancer, and identifica-
tion of cases that are less likely to develop cancer would
enable more accurate targeting of risk reducing and
therapeutic strategies. As such, BRCA1 mutation carrier
testing is another promising application of SELDI-TOF
Study
Belluco et al. [21] Sauter et al. [26] Li et al. [13]
310 114 95
155 patients with stage I invasive ductal carcinoma (IDC) of the breast 155
healthy controls
81 benign diagnosis, 6 ADH, 5
DCIS, and 22 invasive breast
cancer (IBC)
Serum NAF NAF and ductal lavage fluid
IMAC-Cu H4, NP and Q10 IMAC30
5.99255 kDa ↓a Cancer vs. healthy NAF: 5.2,
11.9, and 13.9 kDa
3.38 kDa
5.83850 kDa ↓ DCIS vs. benign disease
differentially expressed
peaks: 5.2 and 33.4 kDa
2.95470 kDa ↓ ADH vs. benign disease:
5.2 kDa
3.45 kDa






These 7 peaks were validated and tested to differentiate stage I breast cancer
from healthy samples, and had strong sensitivity and specificity
Strongest peak was the 15.94







were detected on the 3 chips
in 90% of the runs
Peaks differentiated DCIS from
benign disease, ADH and
IBC
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MS. Studies by Becker [23] and Laronga et al. [16] have
examined the role of SELDI proteomic profiling in patients
with BRCA mutations.
Differentiation Between BRCA1 Cancer and BRCA1
Carrier Groups
In a promising proteomic study, serum samples from 30
BRCA1 carriers, 16 patients with sporadic breast cancer
(SBC) and 16 healthy controls were used (Table 2) [16, 23].
Of the 30 patients with BRCA1 mutations, 15 patients
developed breast cancer within 3 years of follow-up,
whereas the other 15 carriers were cancer-free after 7 years
of follow-up. The mean age of those who developed breast
cancer was 44.2 years and the mean age of those who did
not was 44.6. It is conceivable, given the young age of the
two groups, that many of those who had not developed
breast cancer at the time of the study would ultimately
develop breast cancer despite being placed in the “cancer-
free” group. Nevertheless, the study demonstrated two
peaks that best distinguished between the BRCA1 cancer
and carrier groups. One peak occurred at 8.1 kDa and was
overexpressed in patients who developed breast cancer, and
the other peak was noted at 5.9 kDa and was underex-
pressed in the same group (sensitivity and specificity 100%
in the testing set; 87% on cross validation). The latter peak
was the primary determinant between the two groups.
SELDI-TOF MS accurately differentiated 13 out of the 15
women with BRCA1 mutations who developed cancer from
the 15 BRCA1 mutation carriers who did not (87%
sensitivity and specificity). Whether the distinction in
protein profiles found between the two BRCA1 mutation
groups represents an early detection of a pre-cancerous state
or an occult malignancy remains unclear.
Study
Noble et al. [24] Ricolleau et al. [33] Streckfus et al. [43]
Number 65 60 6
21 cancer
44 healthy
Sample NAF Cytosol Saliva
Array used IMAC30 IMAC-Cu, Q10 CM10
Differential
peaks
Breast cancer vs. healthy:







19.8 kDa SAX 170 kDa
CM10: 3.471 , 3.511,
4.151, 4.586, 4.646,
4.698 kDa










4.417, 4.376, 5.890 kDa




NAF in the breast cancer
group, which might
suggest systemic changes
in women with breast
cancer
Combining St Gallen score
to the 2 peaks led to





treatment in 40% of breast
cancer patients post-
surgery
This small pilot study




healthy subjects in human
saliva
Bold peaks are either validated or detected in different studies or binding surfaces
a Repeatedly detected/validated peaks which present a potential biomarker
Table 2 (continued)
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Becker et al. [23] also examined proteomic profiles in
patients with SBC and healthy controls. Differentiation
between BRCA1 cancer and SBC groups was possible
with a sensitivity of 94% and a specificity of 100% on
cross validation. Additionally, between BRCA1 cancer
and the control group, peak separation was achieved with
87% sensitivity and 94% specificity. As expected, no
single discriminatory peak was detected and separation
between groups was based on a panel of peaks. Finally, in
differentiating between BRCA1 carriers compared to
control groups, the peaks revealed interchangeable profiles
which were not discriminatory. The peaks were, however,
different from both the SBC and BRCA1 cancer groups.
This, therefore, confirmed the distinction between healthy
controls and the SBC group. It is notable that differenti-
ation between BRCA1 cancer group from the BRCA1
carrier group and the SBC group involved the BC2
(8.1 kDa) peak. This was overexpressed in the BRCA1
cancer group and not the other two. Interestingly, a similar
size peak was also shown to be significantly overex-
pressed in breast cancer serum samples studied by Li et al.
[17, 18] and Mathelin et al. [19]. This certainly requires
verification and identification of each protein and could
lead to new era in the molecular understanding of breast
cancer. Despite the small number of samples, the repro-
ducibility of SELDI proteomic profiling published by
multiple investigators is intriguing and necessitates further
large-scale validation.
Comparison of Proteomic Profiles Pre- and Post-surgery
Laronga and coworkers performed proteomic profiling on
paired serum samples from 16 breast cancer patients pre-
and post-surgery and 15 age-matched healthy samples [16]
(Table 2). Profiling yielded three significant differentially
expressed ion peaks between the pre- and post-surgery
groups, and it was possible to differentiate 14 out of 16 of
the post-treatment group from the pre-treatment samples,
with a sensitivity and specificity of 75% and 87%,
respectively.
Work was also performed to investigate whether
samples from breast cancer patients post-surgery could
be differentiated from healthy controls. This is of interest
as if removing the tumor leads to a restoration of the
normal healthy profiles it would be reasonable to link the
characteristic peaks in the profile to the proteins shed or
inhibited by the tumor. In contrast, however, the SELDI
analysis clearly differentiated protein profiles between the
controls and breast cancer patients post-surgery, with a
final separation sensitivity of 93% and specificity of 73%.
The post-treatment group partially retained protein profiles
after surgery, which were absent in healthy individuals
[14].
The Relationship Between Serum Proteomic Biomarker
Profiles and Clinicopathological Variables
Studying the associations between potential proteomic
biomarkers and clinicopathological factors may lend insight
into the biological significance of proteomic profiles. For
example, profiles strongly associated with estrogen receptor
(ER) status might be expected to be due to proteins
involved in hormonal signaling. It is also possible,
however, that the absence of such a correlation with known
clinicopathological variables might be due to the identi-
fication of new independent factors. However, in the
study by Li et al. [17], BC2 and BC3 peaks did not
correlate with tumor size, nodal involvement, tumor grade,
or ER/progesterone receptor (PR) status. The authors
hypothesized that these complement peaks are overex-
pressed in early breast cancer stages but underexpressed in
advanced and metastatic disease. In addition, no correla-
tion was found between the four peaks identified by
Mathelin and colleagues and any clinical or histological
parameters including age, nodal status, metastasis, vascu-
lar invasion, ER/PR, and Ca15.3, suggesting that the four
biomarkers are independent to these factors [19]. Other
groups have further confirmed these findings, demonstrating a
lack of association between these proteomic markers and
tumor characteristics; however, a reduction in the 8.1-kDa
peak intensity noted in the post-menopausal subgroup
warrants further evaluation [20].
Laronga et al. attempted to use SELDI-TOF to distinguish
sentinel lymph node (SLN)-positive from SLN-negative
patients in 98 women [14]. Out of the node-positive group,
22/27 samples were correctly classified compared to 55/71
correctly classified samples in the node-negative group. This
produced a classification tree with a sensitivity of 81% and a
specificity of 77%. The main differentiating factors were
three low mass peaks on the IMAC-Cu and three high mass
peaks on the SAX surfaces. If axillary node status could be
accurately determined using proteomic profiling approaches,
node-negative patients could be spared unnecessary axillary
surgery with its attendant complications.
Nipple Aspirate Fluid Proteomic Profiling
Intraductal sampling and diagnostic techniques include
nipple aspiration, ductal lavage, and duct endoscopy.
These are minimally invasive and allow direct access to
the ductal system where most breast malignancies arise.
This could be particularly useful in young women where
mammographic sensitivities are reduced. Breast duct fluid
is a rich source of protein from the immediate vicinity of
tumors and their local microenvironment and may repre-
sent a superior source of cancer biomarkers due to this
close proximity. Similarly, in early stage in situ (DCIS)
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disease where the basement membrane remains intact,
ductal fluid may contain tumor markers that are excluded
from the systemic circulation. The main disadvantage of
nipple aspirate fluid (NAF), however, lies in the low
cellular yield making cytological analysis difficult. Recent
technological advances have enabled rapid protein bio-
marker identification from small volume NAF using
SELDI-TOF MS.
Nipple Aspirate Fluid Proteomics of the Ipsilateral
Affected Breast in Patients with Breast Cancer Compared
to Controls
Noble et al. [24] compared NAF proteomes from women
with unilateral breast cancer and healthy female controls.
NAF was collected from both breasts of 21 patients newly
diagnosed with unilateral breast cancer and a further 44
samples from healthy subjects with a family history of
breast cancer.
Comparing proteomic profiles of NAF from the ipsilat-
eral affected breast and NAF from healthy controls revealed
six peaks on the CM10 surface and three on the IMAC that
were significantly different between the two groups
(Table 2). Five breast cancer biomarker peaks were
identified that were more frequently expressed in women
with breast cancer compared to women without [25]. The
most promising peak that best distinguished between the
two groups was a 15.9-kDa protein. This protein was
identified on an H4 array with the aid of the virtual tryptic
digest database as the β chain of hemoglobin. Two other
peaks at 8 and 31.8 kDa were identified as the doubly
charged and diameric forms of the same protein, respec-
tively. Clearly, validating this biomarker was critical in this
instance.
To validate this pilot study and to establish a breast
cancer predictive model using NAF protein profiling,
Sauter et al. [26] analyzed NAF from 114 women (Table 2).
None of the previously identified protein peaks were found
to be associated with breast cancer in this study. Seven new
candidates were detected, of which three were associated
with breast cancer (Table 2). These remained significant
discriminators even after excluding women with patholog-
ical nipple discharge and duct papillomas. Furthermore, two
peaks at 5.2 and 33.4 kDa differentiated between DCIS and
benign disease, and the peak at 33.4 kDa differentiated
DCIS from IBC. Importantly, these peaks were consistent
in differentiating DCIS from the benign group, which may
provide an early prediction of the development of neoplas-
tic disease. Overexpression of the peaks at 5.2, 13.88, and
33.4 kDa was also shown to be associated with both DCIS
and IBC but not with atypical ductal hyperplasia (ADH) or
benign disease. The authors also attempted to build a
predictive module using the newly discovered peaks in
association with other clinical variables. A model including
age, parity, and the peak at 11,880 Da using the H4 chip
was found best with a sensitivity and specificity of 40% and
94%, respectively.
In a multicenter study involving 95 patients, Li and
colleagues [13] attempted to profile breast fluid proteomes
obtained from both ductal lavage and NAF. Using an
optimized immobilized metal affinity surface protocol, Li et
al. [13] identified three potential biomarkers which differ-
entiated cancer fluids from controls. Three differentially
expressed peaks (3.375, 3.447, and 3.490 kDa) were
identified as human neutrophil peptides (HNP)1−3 (Table 2).
This was also verified using SELDI-TOF MS immunocap-
ture assay on breast cancer samples which originally
revealed higher HNP1–3 peak intensities. Moreover, Li et
al. [13] used enzyme-linked immunosorbent assay to
quantify the three biomarkers providing further valida-
tion of their findings using SELDI. HNP was shown not
to be the result of blood contamination and had been
previously detected in tissue samples from lung, oral,
colorectal, and renal cancers [27–30]. Their high level in
cancers might be explained by tumor cell invasion and
release of neutrophils and eosinophils, or by direct
secretion of these peptides.
NAF Proteomics of the Contralateral Unaffected Breast
in Patients with Breast Cancer Compared to Ipsilateral
Affected Breast Cancer
While previous studies applying different profiling techni-
ques have shown significant proteomic differences be-
tween NAF from tumor-bearing and normal breasts in
breast cancer patients [31, 32], Noble et al. [24] found no
significant differences between these paired profiles using
SELDI. Comparative profiling between NAF from the
unaffected breast in patients with breast cancer and NAF
from controls was also performed [24], and interestingly,
no differences were noted. While further validation studies
are required, the absence of discriminatory peaks between
the NAF from the ipsilateral affected breast and the
contralateral unaffected breast is striking. These results
led the researchers to hypothesize that in breast cancer a
field change occurs across both breasts, and that NAF
proteomics may have more value in breast cancer risk
assessment, rather than in diagnosis or screening. While
comparison between the two sides from the same
individual is conceivably an attractive approach providing
an internal control for hormonal and environmental
effects, it would not be as informative if this hypothesized
field change takes place. Yet again, this is a suitable
setting for paired SELDI and other proteomic profiling
studies using one cohort to address these conflicting
results.
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Cytosolic Protein Profiling in Breast Cancer
Low abundance biomarker proteins related to tumor cells
or their microenvironment might be diluted, altered, or
fragmented once shed in the bloodstream. This may have
an adverse effect on the results obtained by MS profiling.
Cytosolic extracts represent an alternative source of tissue,
possibly with higher concentrations of the relevant
proteins. Moreover, profiling the cytoplasmic proteome
has the advantage of helping detect novel intracellular
pathways and interactions involved in tumorogenesis.
Alterations in mitochondrial proteins have also been
linked to cancer development and progression and could
be detected by this method. Overall, studying the protein
from the native tumor may lead to important insights into
tumor differentiation, invasiveness, and responsiveness to
adjuvant therapies. Conversely, however, this type of
study is less likely to help with early detection of
carcinogenesis, since by definition, samples are taken
from the tumor.
Node status remains the strongest prognostic marker in
breast cancer and helps determine the need for adjuvant
therapies. Nevertheless, a significant proportion of node-
negative patients develop disease recurrence and earlier
identification and treatment of this high risk group may be
advantageous.
Ricolleau et al. [33] performed cytosolic protein
profiling on 60 samples from patients with node-negative
sporadic breast cancer. Thirty of these patients had
developed a distant relapse and 30 remained disease-free.
Samples were analyzed using IMAC-Cu and SAX chips.
Seventy-three peaks were generated from both arms, and
two of these peaks at 8.5 and 19.8 kDa had prognostic
potential. This was further confirmed by repeated random
sampling, and the 8.5-kDa peak was found to be expressed
at lower levels in patients with metastatic disease while the
19.8-kDa peak was found at higher levels in these patients.
These peaks were further identified as ubiquitin and
ferritin light chain (FLC), respectively, and the results
validated by western blotting and immunohistochemistry.
Combining these new molecular biomarkers of disease
relapse with a pre-existing model for prognostication (The
St. Gallen risk profile age <35, size >20 mm, negative
hormone receptors, grade 3) led to improved discrimina-
tion between the groups of patients who suffered a
systemic relapse and those who did not. This promising
line of work, therefore, supports the notion that proteomic
profiling may one day help improve our ability to classify
patients based on molecular parameters and helps deter-
mine treatment options.
A further study was conducted by Brozkova and
coworkers [14]. Focusing on linking proteomic patterns
to tumor clinicopathological characteristics, this group
examined non-metastatic breast cancer tissue lysates from
105 patients on IMAC30 ProteinChip Arrays. One
hundred thirty peaks were detected, which could cluster
the tumors into five distinct groups differing on tumor
type, nuclear grade, presence of hormonal receptors,
mucin 1 and cytokeratin 5/6, or cytokeratin 14 expression.
This study also showed clustering of biomarker patterns
into five further smaller subgroups associated with tumor
type, hormonal receptor status, and nuclear grade. Hor-
mone receptor expressing luminal group, HER2/neu
positive and the basal high proliferation gene expression
subtypes were generated by hierarchical clustering. Strik-
ingly, this molecular tumor classification was identical to
those generated by complementary DNA genomic expres-
sion profiling [34]. In addition, this study successfully
identified heat shock protein (HSP)27 and Annexin V
within the tumor subgroup biomarker classifiers. Both
proteins were mainly overexpressed in the luminal
subcohort. Overall, this study illustrates the potential
utility of SELDI-TOF MS proteomic approaches in
identifying clinically relevant tumor subgroups and
expanding our understanding of breast cancer tumor
behavior, which is a key step towards individualization
of patient therapy [14, 35].
Salivary Proteomic Profiling in Breast Cancer
The level of many salivary constituents is altered in disease
states compared to healthy controls. For example, there are
differences in the levels of kallikreins, CA125, epidermal
growth factor, and cErb2 in the saliva of healthy compared
to diseased subjects [36–39]. Additionally, the collection of
samples is safe, simple, inexpensive, easily repeatable, and
most importantly non-invasive. Researchers have previously
studied the possibility that saliva may be used to diagnose
systemic diseases [40–42], and Streckfus et al. [43] used
SELDI to detect putative breast cancer markers in saliva.
Pooled reference samples and individual saliva from three
healthy controls and three patients with ductal carcinoma in
situ were analyzed and four differentially expressed protein
peaks detected (Table 2). While this is a small exploratory
study, it demonstrates the sensitivity and threshold of
SELDI-TOF MS in detecting significant differentially
expressed peaks in saliva between different patient groups.
In particular, this feasibility study proved that SELDI can be
used to detect alterations of salivary proteins in cancer. While
the results of this pilot study are encouraging, larger and
blinded validation studies will be required to confirm the
value of the differentially expressed protein peaks detected.
In a more recent study using LC–MS/MS, Streckfus et al.
have provided further support for the notion that salivary
protein profiles can provide useful information to classify
patient populations [44].
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Shortfalls in SELDI-TOF MS Profiling
With the aid of recent advances in proteomic technologies
and mining techniques, the limited number of proteins
detected using serum samples can be augmented. SELDI as
a high-throughput solid phase extraction technology is a
useful means of sample protein extraction, fractionation,
and detection. Accordingly, SELDI was perceived as a
suitable platform to enhance the power of profiling studies
through increasing the analysis of both samples and
proteomic signals. Nevertheless, a low molecular mass
detection preference, added to its selective surfaces and its
semi-quantitative abilities, are all factors that could limit the
detection of biomarkers. Other technical aspects including
its low resolution, the slow progression to validation,
identification, and clinical utility, have all contributed to
the negative views of SELDI-based approaches.
Variability and the lack of sequencing abilities currently
limit the use of SELDI. In addition, discrepant reports
failing to validate earlier SELDI results have cast doubts on
SELDI as a technique [45]. It is known that biased non-
biological variability can result from any minor non-
standardized step(s) in any proteomic profiling work,
starting from sample collection and ending by data
processing and analysis [46–48]. Studies testing the effects
of different variables including storage tubes, clotting time,
incubation temperature, storage temperature, and handling
proved the importance of uniform handling to exclude
systemic pre-analytical inconsistency and false discovery
[49, 50]. Non-standardized protocols in different validation
studies have generated conflicting results including clear
variations in the discriminatory power and direction of
several putative biomarkers. These factors have all raised
concerns on the performance of SELDI [51]. In a real world
setting, however, unifying patient cohorts, collection pro-
tocols, storage conditions, handling, and analysis settings is
a challenging task. Nevertheless, adequately powered
upstream studies analyzing large cohorts would attenuate
this variability effect and select for potential clinically valid
biomarker patterns. Moving from detection to identification
of biomarkers is a well-known limitation of this MS-based
tool. Nonetheless, potent cancer biomarker signatures can
be transiently used in multicenter validation providing a
proof supporting or dismissing their relivance. Identifica-
tion of these markers can then be established using other
conventional downstream methods.
The identification of acute phase proteins or proteins
resulting from exoprotease activities as candidate bio-
markers have also raised concerns about the reliability of
this type of profiling [52]. We believe these findings do not
imply underperformance per se, given that any signal
including proteolytic products and acute response players
can reflect a milestone in tumorogenesis. As long as
candidate biomarkers are validated and do not fall within
the false-positive bracket, their role in cancer evolution and
diagnosis remains viable.
Transparent and standardized biomarker discovery
programs are crucial for any unbiassed studies. Candidate
biomarker validation, verification, and authentication should
be the basis for any future biomarker discovery agendas.
Adopting this strategy with strict standardized protocols
would reduce false positives and recover some of the missing
confidence in this exciting field.
Discussion
Expression profiling and biomarker discovery aims to
provide means for tumor diagnosis, classification, and
prediction of response to therapy and prognosis. This could
potentially lead to the building of robust early detection
modules and personalized effective breast cancer therapies
which would improve outcomes. Genomic expression
profiling can reliably classify and predict outcome in breast
cancer [34, 53]. While huge strides have been made by the
application of such genetic techniques, many crucial
changes at the protein level including post-translational
modifications may clearly be important in carcinogenesis.
Yet, these will not be detected by genomic profiling. It is,
therefore, important to correlate genomic studies with
protein expression patterns and relate these to tumor
classification and clinical outcomes. Proteomic profiling
using SELDI-TOF MS possesses huge potential but
requires considerable further study and development. For
example, Brozkova et al. [14] succeeded in classifying
breast cancer patients into subclasses identical to the ones
established by gene expression profiling [34]. This along
with identification of two potential biomarkers HSP27 and
Annexin V provides evidence to the importance, validity,
and complementary role of SELDI-based profiling in
drawing a complete picture of the molecular basis of breast
cancer.
It has been argued that the LMW serum proteins
discovered by SELDI-based profiling are non-specific
rather than cancer-related proteins. Additionally, recent
studies have also showed that even though some of these
biomarkers may be acute phase reactants belonging to
common coagulation, complement pathways, or epiphe-
nomena of tumor presence [45], they do appear to indicate
tumor cell presence and/or activity [54]. Further work is
clearly required to assess the specificity of these markers
for different diseases and tumor subtypes. To date,
discriminatory proteomic biomarkers identified through
SELDI have been detected in other cancers. Koopman et
al. [55] compared the serum of 60 patients with pancreatic
adenocarcinoma to 60 with benign pancreatic disease and a
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further 60 healthy controls by SELDI. They were able to
discriminate cancers from healthy controls with a sensitivity
and specificity of 78% and 97%, respectively. Ornstein found
that proteomic ion patterns achieved 100% sensitivity and
67% specificity in distinguishing patients with and without
prostate cancer [56], and Petricoin and colleagues reported a
proteomic pattern with 100% sensitivity and 95% specificity
in ovarian cancer detection [57]. Breast cancer serum
profiling, however, remains the focus of many of the studies
applying this MS technology [13, 18, 21, 26, 33, 43, 58].
While caution should be exerted in the interpretation of
these figures due to methodological limitations of some
of the studies concerned, and shortcomings inherent to
the use of sensitivity and specificity figures, these reports
illustrate the applications of SELDI outside of breast
cancer, and some of the potential promise shown by
SELDI in early work.
SELDI-TOF MS with its high-throughput capabilities
and its abilities to process crude biological samples on
different chromatographic surfaces represents a promising
opportunity for large-scale breast cancer proteomic profil-
ing. The current variability of detected biomarkers in
different studies could well be a reflection of biological
variation. As such, this is anticipated to lead to a wide
range of proteomic mapping covering different aspects of
diseases. In this review, the initial results from different
groups applying this technology indicated a broad spec-
trum of potential biomarkers. Each study examined
slightly different aspects of breast cancer with diverse
cohort characteristics, sample collection and storage
techniques, and varied analysis protocols. The detection
of unmatched ion peaks and identified biomarkers in
different studies is, therefore, not a surprising phenome-
non and could also be related to the natural population
differences, stage of the disease when samples were
collected, collection and storage duration, the use of
different up-front sample preparation and/or fractionation
techniques, differences in chips, instrument settings, and
other pre-analytical factors. Evidently, it is difficult at
present to compare results of different studies, as there are
huge variations in pre-analytical conditions used which
would lead to discovery of different subsets of biomarkers.
In addition, the bioinformatics involved in data analysis
represents a further source of variability in this evolving
technology which if unified, could potentially consolidate
proteomic analysis using SELDI.
Avenues for improvements in the application of SELDI
technology in cancer detection would involve comparative
analysis of different types of samples, biostatistical inter-
pretations, as well as involving larger multicenter studies
and standardizing protocols (Zeidan et al., submitted for
publication). One advantage of the SELDI technique is the
ability to use selective surfaces to analyze different
characteristics from the same cohort of samples but the
downside of this is the variability of detected peaks found
in different studies. Planned multicenter studies applying
multiple surface analysis and adjunct tools could eventually
lead to robust biomarker discovery. Since SELDI proteomic
profiling is a relatively newborn technology, it will be
undoubtedly difficult to unify pre-analytical preparation and
analysis. However, where extensive projects are being
carried out, collaboration between groups may facilitate
an organized, supervised, and eventually unified progres-
sion of proteomic mapping of breast and other cancers.
Major clinical trials should also provide a favorable focus
for proteomic analysis within predefined patient groups.
This review describes the potential for early breast cancer
detection and outcome prediction through identification of
protein/peptides biomarker profiles using SELDI-TOF MS.
This supports the rationale for development of SELDI-TOF
and more advanced MS technologies, and the need for larger-
scale standardized validation studies of candidate markers and
their identification.
Key to any biomarker discovery is the translation to
valid bed side application. SELDI profiling as such is not a
valid clinical diagnostic tool. Moreover, a clinical version
of SELDI mined breast cancer biomarkers remains absent.
This could be partly due to a challenging biomarker
identification stage and a time-consuming quantitative
assay optimization and validation. Overall, a lag usually
heralds the transition between biomarker discovery and
clinical application. Here, an immune-based clinical test
would be most optimal. It is anticipated that future work
would reveal new biomarkers or profiles which may
ultimately find practical clinical application in cancer
screening, diagnosis and outcome prediction, and patient-
tailored treatment strategies.
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